MDM2 Protein Inhibitors Therapeutics Clinical Trials & Results
| Main Author: | Pharma Proff |
|---|---|
| Format: | Article Journal |
| Bahasa: | eng |
| Terbitan: |
, 2019
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/2869922 |
Daftar Isi:
- MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the E3 ubiquitin ligase activity of MDM2 and targeting the MDM2-p53 (protein–protein) complex, for the treatment of various indications. Download the sample report @ https://www.pharmaproff.com/request-sample/1205 MDM2 protein therapies have shown positive clinical results for the treatment of various cancers. Also, researches have demonstrated that additional biomarkers are required to be identified to increase the chances of clinical success as mutations in p53 can lead to resistance to MDM2 inhibitors.